More on ADOC
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.85 |
|
|||
| Open | $146.20 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.85 | ||||
| Day Low | $2.85 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 2,595,274 | ||||
- Number of Shares and Voting Rights of ADOCIA as of May 31st, 2026
- ADOCIA Confirms its Eligibility for the PEA‑PME Scheme
- ADOCIA presents phase 3 data for diabetes insulin at ADA conference
- ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025
- Adocia to host virtual event on Phase 3 insulin trial results
- Adocia Announces a Virtual KOL Event to Review the Phase 3 Results of the Ultra-Rapid Insulin BioChaperone® Lispro on June 16, 2026
- ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update
- ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 3rd, 2026 in Paris
- Number of Shares and Voting Rights of ADOCIA as of April 30, 2026
- ADOCIA Announces the Release of its Universal Registration Document for the Year 2025
Entities mentioned with ADOC
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- SPAC | View Related Stories »
- FDA | View Related Stories »
- IPO | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
